Effect of recombinant human brain natriuretic peptide combined with furosemide in improvement of cardiac function and blood gas indicators in patients with acute myocardial infarction complicated with heart failure

Objective To investigate the improvement effect of recombinant human brain natriuretic peptide (rhBNP) combined with furosemide on cardiac function and blood gas indicators in patients with acute myocardial infarction (AMI) complicated with heart failure.

Methods A total of 152 patients with AMI complicated with heart failure were selected and randomly divided into control group and observation group using a random drawing method, with 76 patients in each group. The control group was treated with furosemide, while the observation group received a combination therapy of rhBNP and furosemide. Changes in cardiac function and blood gas indicators before and after treatment were observed in both groups, and the therapeutic effects and adverse reactions during medication were compared.

Results Cardiac function indicators and arterial blood gas indicators in both groups were significantly improved after treatment compared with those before treatment. Additionally, the left ventricular ejection fraction (LVEF), blood oxygen saturation (S_aO₂), and partial pressure of oxygen p_a(O₂) levels were higher, while the left ventricular end-diastolic volume (LVEDV), left ventricular end-systolic volume (LVESV), and partial pressure of carbon dioxidep_a(CO₂)levels were lower in the observation group compared to the control group (P < 0.05). After treatment, the levels of serum creatinine (SCr) and creatine kinase isoenzyme (CK-MB) decreased, and the level of myoglobin (Mb) increased significantly in the observation group, which were better than those in the control group (P < 0.05). The total effective rate of treatment in the observation group was significantly higher than that in the control group (90.79% versus 60.53%, P < 0.05). There was no statistically significant difference in the total incidence of adverse reactions during medication between the two groups (P>0.05).

Conclusion The clinical treatment of AMI complicated with heart failure using a combination of rhBNP and furosemide has a significant improvement effect on cardiac function and blood gas indicators, with a definitive therapeutic effect and no increase in adverse reactions, thus it is better in safety.